What's Happening?
A study by Break Through Cancer has discovered that nearly half of ovarian cancer patients in remission still harbor hidden cancer cells. The research, conducted by a multi-institutional team, utilized minimally invasive surgery and blood tests to detect minimal residual disease (MRD) in patients who appeared cancer-free on scans. The study found that 42% of patients had lingering cancer cells, which conventional tests would have missed. Researchers identified specific druggable targets and biological features that may explain why some cancer cells survive treatment, offering new avenues for therapy.
AD
Why It's Important?
The findings highlight the limitations of current imaging techniques in detecting residual cancer cells, which can lead to recurrence in ovarian cancer patients. By identifying MRD, the study provides a pathway for developing more effective treatments and personalized care strategies. The use of circulating tumor DNA as a blood-based tool to detect MRD offers a non-invasive method to monitor disease progression, potentially improving patient outcomes and reducing the need for surgical interventions. This research could lead to faster clinical trials and access to new therapies, addressing a critical need in the treatment of advanced ovarian cancer.
What's Next?
The study is part of a broader initiative to understand and intercept MRD across various cancers. Ongoing trials funded by Break Through Cancer are evaluating novel immunotherapies targeting MRD. The research aims to reshape how ovarian cancer is studied and treated, with the potential to develop curative treatments. The findings also encourage collaboration among leading cancer research institutions to drive innovative solutions for hard-to-treat cancers.
